First Trust Capital Management L.P. purchased a new stake in Bio-Techne Corp (NASDAQ:TECH – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,786 shares of the biotechnology company’s stock, valued at approximately $1,724,000.
Other large investors also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Bio-Techne in the 3rd quarter valued at $539,000. Maryland State Retirement & Pension System grew its position in Bio-Techne by 10.7% during the third quarter. Maryland State Retirement & Pension System now owns 9,205 shares of the biotechnology company’s stock valued at $667,000 after buying an additional 891 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Bio-Techne during the third quarter valued at $1,141,000. Machina Capital S.A.S. acquired a new stake in Bio-Techne during the third quarter valued at $1,764,000. Finally, Lido Advisors LLC purchased a new position in Bio-Techne in the third quarter valued at $663,000. 98.95% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on TECH shares. Benchmark reiterated a “hold” rating on shares of Bio-Techne in a research report on Wednesday, August 19th. Zacks Research raised shares of Bio-Techne from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 29th. Wells Fargo & Company cut Bio-Techne from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $62.00 to $73.00 in a research report on Thursday, August 13th. Argus lowered Bio-Techne from a “strong-buy” rating to a “strong sell” rating in a research note on Monday, October 26th. Finally, Weiss Ratings raised Bio-Techne from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Techne presently has a consensus rating of “Hold” and an average price target of $68.92.
Read Our Latest Stock Report on TECH
Bio-Techne Price Performance
Shares of NASDAQ TECH opened at $72.80 on Monday. The company’s 50-day simple moving average is $72.53 and its 200-day simple moving average is $63.48. Bio-Techne Corp has a 52-week low of $43.19 and a 52-week high of $72.88. The firm has a market cap of $11.44 billion, a price-to-earnings ratio of 66.79, a price-to-earnings-growth ratio of 5.28 and a beta of 1.29.
Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The biotechnology company reported $0.44 earnings per share for the quarter, hitting the consensus estimate of $0.44. The firm had revenue of $299.71 million during the quarter, compared to the consensus estimate of $292.60 million. Bio-Techne had a net margin of 13.95% and a return on equity of 13.00%. Equities research analysts anticipate that Bio-Techne Corp will post 1.75 EPS for the current fiscal year.
Bio-Techne Cuts Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 23rd. Shareholders of record on Friday, November 13th will be paid a dividend of $0.08 per share. This is a decrease from Bio-Techne’s previous quarterly dividend of $0.65. The ex-dividend date is Friday, November 13th. This represents a $0.32 annualized dividend and a yield of 0.4%. Bio-Techne’s dividend payout ratio (DPR) is presently 29.36%.
About Bio-Techne
Bio-Techne is a life sciences company that develops and supplies products and services used in biological research, drug development, and clinical diagnostics. Its offerings include proteins, antibodies, immunoassays, and small molecules, as well as instruments and analytical tools for studying cells and biological processes. The company also provides technologies for protein analysis, molecular diagnostics, and spatial biology. Its portfolio includes products and services associated with brands such as R&D Systems, Tocris, ProteinSimple, and Advanced Cell Diagnostics.
See Also
- Five stocks we like better than Bio-Techne
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.
